Biotech Showcase™ 2016: Interview: F-star CEO details asset-centric ambitions

Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director of content for Informa's pharma insights products, how the company is looking to raise an additional USD 30 million this year to help the company move some of its own programs into the clinic within 18 months. Dr. Haurum describes differences in the deals involving F-star alpha, an option deal with Bristol-Myers Squibb, and F-star beta which will see AbbVie get access to assets that will allow it to create bispecific antibodies targeting two particular immuno-oncology checkpoints.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights